The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.25
Bid: 21.00
Ask: 21.50
Change: 0.25 (1.19%)
Spread: 0.50 (2.38%)
Open: 21.25
High: 21.40
Low: 21.25
Yest. Close: 21.00
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Scancell selects Covid-19 vaccine candidate for development and trials

Fri, 18th Dec 2020 10:17

(Sharecast News) - Immunotherapy developer Scancell has selected its Covid-19 vaccine candidate 'SN14' for further development and clinical trials, it announced on Friday.
The AIM-traded firm said SN14 targets both the SARS-CoV-2 nucleocapsid (N) protein, and the key receptor-binding domain of the spike (S) protein, and was based on a modification of Scancell's 'ImmunoBody' DNA vaccine technology.

It said 15 vaccine candidates containing different S and N components, combined with a variety of targeting technologies, were evaluated for the best T-cell and antibody responses.

SN14 reproducibly elicited high-titre anti-S virus neutralising antibodies, together with high avidity T-cells against both the S and N proteins, Scancell explained.

It said SN14 also incorporated its 'AvidiMab' technology to further enhance the immune response.

SN14 was described as a second generation vaccine, which offered several potential advantages over currently-approved and late-stage Covid-19 vaccines.

It explained that SN14 both targeted the S protein to induce virus neutralising antibodies that prevent the Covid-19 virus from entering cells, and induced "strong" T-cell responses to both the S and N proteins, to destroy virally-infected cells and prevent further viral replication.

As the N protein was "well-conserved" between coronaviruses, Scancell claimed the SN14 vaccine had the potential to be effective against any variant or new strain of coronavirus, in addition to the current Covid-19 strain.

Use of the 'AvidiMab' technology increased the potency of the T-cell response, the board claimed, which in turn should lead to long-term protection and immunological memory.

It also said that DNA vaccines were "exceptionally stable", did not require ultra-low temperature storage, and were manufactured using relatively simple processes.

As it reported in October, Scancell had entered into a collaboration with Cobra Biologics, part of the Cognate BioServices family, to conduct preliminary work leading to the manufacture of SN14 with the goal of starting a phase 1 'COVIDITY' clinical trial as soon as possible during 2021.

The project was funded by an Innovate UK grant awarded to a consortium between Scancell, the University of Nottingham and Trent University.

"We are very excited about our SN14 second generation Covid-19 vaccine which could have significant advantages over first generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long term protection," said chief scientific officer Lindy Durrant.

At 1052 GMT, shares in Scancell Holdings were up 16.39% at 13.97p.

More News

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

7 Jun 21 13:58

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

7 Jun 21 10:38

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

30 Apr 21 14:30

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

19 Feb 21 20:13

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

19 Feb 21 12:40

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

17 Feb 21 16:22

Scancell ends clinical development partnership with Cancer Research UK

(Sharecast News) - Novel immunotherapy developer Scancell updated the market on its SCIB2 clinical development partnership with Cancer Research UK on Wednesday, reporting that due to the impact of the Covid-19 pandemic and Cancer Research UK's re-evaluation of its collaboration model, the parties had agreed to end their clinical development partnership.

3 Feb 21 14:53

CORRECT: AIM WINNERS & LOSERS: Brave Bison Charges Ahead

CORRECT: AIM WINNERS & LOSERS: Brave Bison Charges Ahead

3 Feb 21 11:20

AIM WINNERS & LOSERS: Brave Bison Charges Ahead On Contract Win

AIM WINNERS & LOSERS: Brave Bison Charges Ahead On Contract Win

3 Feb 21 11:11

Scancell Assessing SCIB2 Options As Cancer Research UK Pact Ends

Scancell Assessing SCIB2 Options As Cancer Research UK Pact Ends

3 Feb 21 09:48

IN BRIEF: Scancell Posts Interim Pretax Loss; To Develop Virus Vaccine

IN BRIEF: Scancell Posts Interim Pretax Loss; To Develop Virus Vaccine

29 Jan 21 15:05

Oxford Technology VCTs In Mixed Quarter Amid Scancell Rise, Ixaris Hit

Oxford Technology VCTs In Mixed Quarter Amid Scancell Rise, Ixaris Hit

21 Dec 20 19:39

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

18 Dec 20 10:45

Scancell Shares Rise As It Chooses Vaccine Candidate For Development

Scancell Shares Rise As It Chooses Vaccine Candidate For Development

18 Dec 20 10:26

Scancell selects Covid-19 vaccine candidate for development and trials

(Sharecast News) - Immunotherapy developer Scancell has selected its Covid-19 vaccine candidate 'SN14' for further development and clinical trials, it announced on Friday.

18 Dec 20 10:17

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.